Senior Research Scientist
Day Zero Diagnostics
Chiahao (Kevin) Tsui received his doctorate from University of California, Berkeley in 2017. Working in the lab of Professor Robert Tjian, he leveraged the versatility and specificity of the CRISPR/Cas9 system to develop CLASP, a novel reverse-ChIP method that couples chromatin purification to mass spectrometry for identifying a picture of the protein ensemble operating at the DNA sequence of interest.
After graduation, Kevin moved to Boston and joined Day Zero Diagnostics (DZD), where he has been a part of the team developing DZD’s species-agnostic bacteremia identification/ antibiotic susceptibility pipeline and validating it across 45+ bacterial species. When he’s not in the lab, Kevin enjoys exploring Boston with his wife, 2 dogs, and cat.
Disclosure: Day Zero Diagnostics (Individual(s) Involved: Self): Employee, Shareholder
